Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes
| Autor: | R. Brigg Turner, Hollis R. O’Neal, Nancy F. Crum-Cianflone, Eva Sullivan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.drug_class 030106 microbiology Antibiotics review Neutropenia 03 medical and health sciences 0302 clinical medicine Internal medicine hemic and lymphatic diseases medicine neutropenia 030212 general & internal medicine Review Articles Series (stratigraphy) business.industry Incidence (epidemiology) medicine.disease side effects Infectious Diseases Oncology Individual study Median time Absolute neutrophil count incidence ceftaroline business |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| Popis: | Ceftaroline is increasingly prescribed for “off-label” indications involving longer durations and higher doses. There have been postmarketing case reports of neutropenia among patients who have received extended durations of ceftaroline, but limited published data currently exist on its incidence and risk factors. We review a total of 37 published cases of ceftaroline-associated neutropenia including cases (n = 4) identified in our health care system. The median time from ceftaroline initiation to development of neutropenia (range) was 25 (8–125) days, with a median duration of neutropenia (range) of 4 (1–16) days. Agranulocytosis (absolute neutrophil count [ANC] nadir < 100 cells/mm3) developed in 49% of cases (n = 18), and there was an ANC nadir of 0 in 27% (n = 10). The overall incidence of neutropenia among cases receiving ceftaroline for ≥7–14 days (range) was 12% (7%–18% per individual study), higher than for comparator antibiotics in the literature. Risk factors for ceftaroline-associated neutropenia varied among studies and remain poorly defined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |